Pfizer Inc. Stock
Pfizer Inc. Stock
There is nearly no change for the Pfizer Inc. stock today. Compared to yesterday it only changed by -€0.020.
With 28 Buy predictions and 2 Sell predictions Pfizer Inc. is one of the favorites of our community.
With a target price of €36.00 there is a positive potential of 29.894% for Pfizer Inc. compared to the current price of €27.72.
Our community identified positive and negative aspects for Pfizer Inc. stock for the coming years. 7 users see the criterium "Brand" as a plus for the Pfizer Inc. stock. On the other hand our users think that "Non-cyclic/Cyclic" could be a problem in the future.
With 28 Buy predictions and 2 Sell predictions Pfizer Inc. is one of the favorites of our community.
With a target price of €36.00 there is a positive potential of 29.894% for Pfizer Inc. compared to the current price of €27.72.
Our community identified positive and negative aspects for Pfizer Inc. stock for the coming years. 7 users see the criterium "Brand" as a plus for the Pfizer Inc. stock. On the other hand our users think that "Non-cyclic/Cyclic" could be a problem in the future.
Pros and Cons of Pfizer Inc. in the next few years
Pros
7
Known brand
7
Could be worthwhile Investment >10% per year
6
Market Leader or Top 3
Cons
4
Significant cyclical dependencies
3
Sustainability is little important
Performance of Pfizer Inc. vs. its peers
| Security | Change (%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. | -0.070% | -4.296% | -7.765% | -8.648% | -8.314% | -0.569% | 7.671% |
| Eli Lilly Corp. | -0.460% | -1.948% | -0.732% | 32.077% | 23.665% | 163.244% | 151.248% |
| Alexion Pharmaceutical Inc. | -0.550% | -2.577% | -3.215% | 39.169% | -0.657% | 35.676% | -1.854% |
| Johnson & Johnson | 1.060% | -2.835% | -0.595% | -0.669% | 5.945% | 24.590% | 40.178% |
Comments
Buy Pfizer Inc.
Buy with target price 72.0
Other discussions about Pfizer Inc. Stock
Trading Pfizer Inc.
Trading Pfizer Inc.
News
U.S. FDA Accepts for Priority Review Pfizer’s Application for TicoVac™ (Tick-borne Encephalitis Vaccine)
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review the company’s Biologics License Application (BLA) for TicoVac™, its tick-borne
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Angela Hwang, Group President, Pfizer Biopharmaceuticals Group, at the Cowen 41st Annual
Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab (PF-06863135) in Multiple Myeloma
Pfizer Inc. (NYSE:PFE) today announced that the first participant has been dosed in the registration-enabling Phase 2 MagnetisMM-3 study (NCT04649359) of elranatamab (PF-06863135), an
